Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 11, Issue 3, pp. 752-762
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 19, 2011
- Revision received December 1, 2011
- Accepted December 21, 2011
- Published first January 5, 2012.
Article Versions
- Previous version (January 5, 2012 - 15:22).
- Previous version (February 21, 2012 - 13:35).
- You are viewing the most recent version of this article.
Copyright & Usage
©2012 American Association for Cancer Research.
Author Information
- Cinthia V. Pastuskovas1,
- Eduardo E. Mundo1,
- Simon P. Williams1,
- Tapan K. Nayak2,
- Jason Ho1,
- Sheila Ulufatu1,
- Suzanna Clark1,
- Sarajane Ross1,
- Eric Cheng1,
- Kathryn Parsons-Reponte1,
- Gary Cain1,
- Marjie Van Hoy1,
- Nicholas Majidy1,
- Sheila Bheddah1,
- Josefa dela Cruz Chuh1,
- Katherine R. Kozak1,
- Nicholas Lewin-Koh1,
- Peter Nauka1,
- Daniela Bumbaca1,
- Mark Sliwkowski1,
- Jay Tibbitts1,
- Frank-Peter Theil1,
- Paul J. Fielder1,
- Leslie A. Khawli1, and
- C. Andrew Boswell1
- Authors' Affiliations: 1Genentech Research and Early Development, South San Francisco, California; and 2Pharma Research and Early Development, Hoffmann-La Roche Ltd., Basel, Switzerland
- Corresponding Authors:
Leslie A. Khawli, Early Development Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, CA 94080. Phone: 650-225-6509; Fax: 650-742-5234; E-mail: khawli.leslie{at}gene.com; and C. Andrew Boswell, Phone: 650-467-4603; Fax: 650-742-5234; E-mail: boswell.andy{at}gene.com
March 2012
Volume 11, Issue 3
Volume 11, Issue 3
Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
Jump to section
Advertisement